1. Introduction {#sec1-nutrients-11-02041}
===============

Keeping a patient hospitalized for the sole purpose of administering nutritional support has become an inappropriate decision from a bio-psycho-social perspective, and wasteful for health institutions and for society from an economic perspective. The introduction of home enteral nutrition (HEN) involves the concerns of correctly selecting candidates, applying a good training programme to the patient and the caregiver, ensuring the supply of formula and necessary materials, providing adequate follow-up and monitoring the quality of patient care \[[@B1-nutrients-11-02041]\].

Interestingly, Parsons et al. \[[@B2-nutrients-11-02041]\] concluded that for patients admitted to nursing homes, oral nutritional support could improve the quality of life and nutrient intake more effectively than dietary advice.

In Spain, HEN is included and regulated in the portfolio of services of the National Health System \[[@B3-nutrients-11-02041]\]. This legislative norm, along with the benefits of HEN itself and the development of nutrition units and home hospitalization units \[[@B4-nutrients-11-02041]\], have made this method of nutritional support (NS) the primary choice for patients who are malnourished or are at risk of malnutrition and have preserved digestive system function but cannot meet their nutritional requirements by natural nutrition alone \[[@B5-nutrients-11-02041]\].

HEN is a safe procedure \[[@B6-nutrients-11-02041]\] whose complications can be predicted and controlled by protocols that consider the formula prescription, the route of administration, the care, the selection of the formula to be used and the feeding modality \[[@B7-nutrients-11-02041]\]. In addition, NS helps improve the patient's quality of life \[[@B8-nutrients-11-02041],[@B9-nutrients-11-02041]\].

Knowing the HEN-related complications is crucial to achieving the objectives of this therapy and to determining its safety level outside the hospital setting, which justifies this study. For the nutritional treatment to be carried out effectively and safely, it is essential that the patient and/or the main caregiver acquires a degree of responsibility in managing the administration of nutrition and, above all, can detect the first signs or symptoms of possible complications. Caregivers must provide the first point of care and demand proper healthcare services for the patient.

The different types of complications and possible medical interventions associated with HEN are already known \[[@B7-nutrients-11-02041],[@B8-nutrients-11-02041],[@B9-nutrients-11-02041],[@B10-nutrients-11-02041]\]. However, the elements that can influence the incidence of HEN-related complications have not been determined. Consequently, due to the limited understanding of enteral formula administration methods and their association with complications, this study aims to determine the association between HEN administration modality and the complications presented by patients.

2. Methods {#sec2-nutrients-11-02041}
==========

2.1. Study Design {#sec2dot1-nutrients-11-02041}
-----------------

This is a prospective and multicenter longitudinal study.

2.2. Setting {#sec2dot2-nutrients-11-02041}
------------

The study involved 15 Spanish hospitals from 7 different autonomous communities: Valencia, Madrid, Cantabria, Canarias, Andalucía, Aragón, and Baleares. Recruitment was carried out from April 2015 to March 2017. The data collection and follow-up period for the patients included in the study was 4 months and was conducted through home visits.

2.3. Participants {#sec2dot3-nutrients-11-02041}
-----------------

Inclusion criteria: Adult patients (≥18 years) who were admitted to the participating home hospitalization units or were dependent on nutrition units, who began their nutrient intake by tube feeding, known as home enteral nutrition (HEN), during the recruitment period.

During the four month follow-up a monthly visit was carried out by the head of each of the participating hospitals, moment in which the patient or their caregiver reported on the adverse effects incurred.

All patients had to provide informed consent to be included in the study. In cases where the patient's situation did not allow for this, consent was obtained from the primary caregiver.

2.4. Ethical Requirements {#sec2dot4-nutrients-11-02041}
-------------------------

The protocol used in this work was approved by the Clinical Research Ethics Committee of the General University Hospital of Alicante (Hospital General Universitario de Alicante), dated January 8, 2014 (registration number CE20PI2013/40).

2.5. Data Collection {#sec2dot5-nutrients-11-02041}
--------------------

The data logging was performed through a platform available on the Internet (<http://www.cafane.net/>), which provided an ad hoc questionnaire developed for this study. The questionnaire complied with all data protection regulations; therefore, it did not record any patient personal data. The participating researchers were granted personalized access (username and password). The questionnaire variables are listed below.

Variables related to the type and modality of HEN administration.

Type of formula administered: standard, specific and others (hypercaloric, hyperproteic, hypercaloric-hyperproteic); HEN with fiber: yes or no; Route of administration: percutaneous endoscopic gastrostomy (PEG), nasogastric tube (NGT) and other ostomies (including jejunostomy); Feeding modality: bolus feeding, intermittent gravity, other modalities (including continuous gravity or pump feeding); Administration time of each intake in minutes; Number of intake periods per day; Dose volume (mL); Total daily volume (mL); Washing of the probe: yes or no; Position during intake (≥45° or \<45°) and after intake (at least 1 h) \[[@B11-nutrients-11-02041]\].

2.6. HEN-Related Complications {#sec2dot6-nutrients-11-02041}
------------------------------

Digestive complications: vomiting, regurgitation, constipation, diarrhea and abdominal distention; Mechanical complications: tube obstruction; Other complications: aspiration pneumonia (bronchoaspiration).

2.7. Descriptive and Fitting Variables {#sec2dot7-nutrients-11-02041}
--------------------------------------

Gender: man or woman; Age: in years; Weight: in kilograms (kg) (if the weight could not be obtained by direct measurement, it was estimated according to gender, age, arm circumference and knee height using the "Malnutrition Universal Screening Tool" \[[@B12-nutrients-11-02041]\]); Height: in meters (m) (if the height could not be obtained, it was estimated by the length of the forearm \[[@B12-nutrients-11-02041]\]); Body mass index (BMI): weight (kg) divided by the height squared (m); Place of residence: family home or social-health institution; Caregiver: family member, paid family member, employee, volunteer or without caregiver; Diagnostic groups: neurological, oncological, and with other diagnoses.

2.8. Statistical Analysis {#sec2dot8-nutrients-11-02041}
-------------------------

For the qualitative variables, the absolute and relative frequencies (percentages) were calculated. For the quantitative variables, the mean and its standard deviation, the median (Me), the interquartile range (IQR) and the standard deviation were calculated.

The association between the qualitative variables was analyzeanalyzed by the chi-squared test, while Student's t-test was used for the quantitative variables to verify the significance of the difference in means for the independent samples. To compare the means between more than 2 groups for a quantitative variable, analysis of variance (ANOVA) was performed using the Tukey method.

The incidence rate (IR) was calculated to find the number of complications involved in the study period (4 months).

A logistic regression model was applied using each of the different complications as a dependent variable (0 = no complication, 1 = one or more complications). The independent variables were route of administration (1 = PEG, 2 = NGT; 3 = other ostomies); feeding modality (1 = intermittent gravity, 2 = bolus feeding, 3 = other modalities); fiber (1 = yes; 2 = no); administration time; number of intake periods; volume of intake; and total volume. All models included the following variables: gender, age, BMI, place of residence, caregiver, and diagnostic group. The probability was measured by the odds ratio (OR).

The level of significance used in all hypotheses was *p* ≤ 0.05.

Quality control of the data was carried out through double tables, and the potential errors were corrected by consulting the originals. The statistical software IBM SPSS Statistics for Windows, version 23.0 (IBM Corp, Armonk, NY, USA) was used to analyze the data.

3. Results {#sec3-nutrients-11-02041}
==========

The data from 306 patients were included; 4 patients were lost due to death. The descriptive data of the population is presented in [Table 1](#nutrients-11-02041-t001){ref-type="table"}. The results show that the place of residence was primarily the family home (224 patients, 73.2%). With the exception of 16 patients (5.2%), most had some type of caregiver, generally a relative (226 patients, 73.9%), and this person was usually a woman (246 cases, 80.4%).

The base pathology did not influence the relationship of the complications associated with the HEN modality.

No intergroup associations were found between the BMI and the mean of the majority of the complications: vomiting (*p* = 0.054), regurgitation (*p* = 0.415), constipation (*p* = 0.401), diarrhea (*p* = 0.113) and probe obstruction (0.204). However, there were significant differences in abdominal distension between the normal weight and obese groups (*p* = 0.040) and for aspiration pneumonia among the overweight and obese groups (*p* = 0.031).

Regarding the HEN-related variables, all of the patients were tube-fed, with 254 (83.0%) patients being exclusively tube-fed, while 52 (17.0%) took in some food orally. The HEN-related descriptive results and the HEN administration modalities are presented in [Table 2](#nutrients-11-02041-t002){ref-type="table"}.

The most frequent complications recorded in the 4 months of follow-up were digestive, predominantly abdominal distension, with an IR of 2.4, while regurgitation had an IR of 2.2. Aspiration pneumonia presented the lowest IR of 0.1. Some significant differences were found, with higher values in men for abdominal distension (3.5 versus 1.1, *p*-value 0.001) and constipation (3.5 versus 1.1, *p*-value 0.001). The number of episodes (*n*) and the IRs of HEN-related complications are shown in [Table 3](#nutrients-11-02041-t003){ref-type="table"}.

4. Complications Related to the HEN Type and Modality {#sec4-nutrients-11-02041}
=====================================================

When analyzing the pre- and post-fitting results regarding the relation between complications and the type of formula used (see [Table 4](#nutrients-11-02041-t004){ref-type="table"}), it was found that the use of a specific HEN formula protected against regurgitation episodes (OR = 0.5 in pre-fitting; OR = 0.4 in post-fitting) and constipation (OR = 0.5 in pre-fitting; OR = 0.4 in post-fitting). On the other hand, the use of other formulas (hypercaloric, hyperproteic, hypercaloric-hyperproteic) was associated with a greater incidence of aspiration pneumonia (OR = 2.4 in pre-fitting; OR = 2.7 in post-fitting).

The use of NGT presented less risk of diarrhea compared to PEG (OR = 0.3 in pre-fitting; OR = 0.4 in post-fitting). Likewise, in the post-fitting results, NGT showed a lower risk of vomiting (OR = 0.4), regurgitation (OR = 0.4) and abdominal distension (OR = 0.5). However, a greater risk of probe obstruction was observed (OR = 7.4).

Regarding the feeding modality, the use of intermittent gravity was a protective factor against vomiting (OR = 0.4, in pre-fitting and post-fitting), regurgitation (OR = 0.3, in pre-fitting and post-fitting), constipation (OR = 0.4 in pre-fitting; OR = 0.3 in post-fitting), diarrhea (OR = 0.5 in pre-fitting; OR = 0.4 in post-fitting) and abdominal distension (OR = 0.3 in pre-fitting; OR = 0.4 in post-fitting) when compared to bolus feeding. However, in the case of abdominal distension, other feeding modalities were also more favourable than bolus feeding (OR = 0.2 in pre-fitting; OR = 0.1 in post-fitting).

The use of HEN with fiber presented a lower risk of constipation (OR = 0.2, in pre-fitting and post-fitting).

The increase in the number of doses represented a risk for the appearance of regurgitation (OR = 1.3 in pre-fitting and post-fitting) and for the obstruction of the catheter (OR = 1.9 in pre-fitting; OR = 1.7 in post-fitting). Likewise, the intake position was associated with probe obstruction (OR = 0.1 in pre-fitting and post-fitting).

The post-fitting results showed association with an increased risk of diarrhea when the administration time (OR = 4.5) and the dose volume (OR = 1.4) increased.

The results of the complications related to the type and modality of HEN administration are shown in [Table 4](#nutrients-11-02041-t004){ref-type="table"}.

5. Discussion {#sec5-nutrients-11-02041}
=============

This study enabled us to determine the complications associated with enteral nutrition administration in a considerable number of patients over a period of several months, which is a strength of this study.

In terms of their pathology, the studied patients presented similar characteristics as those of previous studies---they were older adults with neurological or oncological disease, with a dependence on and a need for a caregiver \[[@B13-nutrients-11-02041],[@B14-nutrients-11-02041]\].

There was no clear significant association between the BMI and the complications resulting from HEN, although a greater number of complication episodes in relation to obesity was observed, a situation already highlighted by Wiggins et al. \[[@B15-nutrients-11-02041]\].

Given the median age of the studied population, it is normal in the Spanish socio-cultural context that the place of residence was primarily the family home, a nucleus with sufficient roots and a caretaker tradition. Likewise, the fact that the main caregiver is typically a woman has been widely noted in the scientific literature \[[@B16-nutrients-11-02041],[@B17-nutrients-11-02041]\] and must be considered when implementing an artificial nutrition regimen, since it can be a great burden for the caregiver \[[@B18-nutrients-11-02041]\].

The greater use of PEG compared to NGT, common in the participating health centers, contrasts with previous research that observed a greater tendency to use NGT in older adults \[[@B1-nutrients-11-02041],[@B14-nutrients-11-02041],[@B19-nutrients-11-02041]\]. In any case, gastrostomy is associated with greater efficacy and safety compared to NGT \[[@B20-nutrients-11-02041]\].

Bolus feeding continued to be used with a greater frequency, though it could be inferred that the infusion speed is not easy to regulate, and there could be alterations in the administration that would lead to some complications. On the other hand, the formula type, the volume administered and the number of doses were all within normal ranges, and it was not surprising that a formula with fiber was administered to patients with long-term HEN, a recommended practice in the absence of contraindicateons \[[@B21-nutrients-11-02041]\].

The IR of HEN-related complications demonstrated the intimate relationship with the route and administration modality. The correct management of HEN reduces these complications and minimizes laryngopharyngeal reflux \[[@B22-nutrients-11-02041]\].

The differences in the observed complications between men and women show an important gender background. Women typically take better responsibility for their own healthcare, especially regarding communication between the patient and the doctor, the understanding of the disease, and their attitudes at the end of life \[[@B23-nutrients-11-02041],[@B24-nutrients-11-02041]\].

6. Complications Related to the Type and Modality of HEN Administration {#sec6-nutrients-11-02041}
=======================================================================

It is important to know that specific formulas are associated with fewer episodes of regurgitation and constipation. However, in many patients, these complications are already present before the initiation of HEN therapy. Therefore, the addition of prokinetic drugs would be useful to prevent regurgitation. In addition, constipation is more frequent than diarrhea in patients fed exclusively by HEN \[[@B25-nutrients-11-02041]\].

The current evidence does not allow us to determine the causes of the increased risk of aspiration pneumonia in nonspecific HEN; the evidence could possibly indicate a recommendation for using a post-pyloric probe, but it is not certain \[[@B26-nutrients-11-02041]\].

Regarding the administration modality, PEG has become the method of choice for enteral feeding in the medium and long term. Most of the complications related to PEG are minor; however, rare major complications can be more serious. The increased risk of diarrhea, vomiting and regurgitation that was observed in this study in relation to PEG was mainly associated with abdominal distension and could show a stronger relation with the administration modality and the volume of the shot. Some complications occur shortly after tube placement; others develop later when the gastrostomy tract has matured. Senior patients with comorbidities and infections appear to be at greater risk of developing complications \[[@B27-nutrients-11-02041]\]. Gomes et al. \[[@B20-nutrients-11-02041]\] demonstrated the nonexistence of significant differences in mortality rates or adverse events, including aspiration pneumonia, between comparison groups (PEG versus NGT). However, they pointed out that factors such as the demographics of the participants, the underlying diseases, age, gender and the gastrostomy technique should be considered. In this sense, Gomez-Candela et al. \[[@B19-nutrients-11-02041]\] indicated that to achieve a low incidence of complications, it was essential to establish an adequate educational programme.

Bolus feeding has been associated with virtually all gastrointestinal complications, and this feeding modality may explain the increased infusion rate, with an abrupt change in the gastrointestinal walls or rapid temperature change. Contrary to these findings, a previous study by Kadamani et al. \[[@B28-nutrients-11-02041]\] did not find differences in the incidence of complications between both administration modalities. However, according to scientific evidence, continuous nutrition should always be chosen for infants with birth weights below 1250 g or infants with haemodynamic deterioration \[[@B29-nutrients-11-02041]\].

Likewise, the present study has shown that an enteral diet containing fiber is a protective factor against intestinal motility disorders \[[@B25-nutrients-11-02041],[@B30-nutrients-11-02041]\].

It has also become clear that an increase in the number of doses and the volume of the intake cause greater gastrointestinal problems and that the patient's position upon intake is related to the possibility of probe obstruction.

7. Conclusions {#sec7-nutrients-11-02041}
==============

It can be concluded that there was a higher incidence of gastrointestinal complications. However, an adequate choice of the formula type, the route and feeding modality, the number of doses, administration time and volume of intake can greatly reduce the IR. Therefore, to reduce these complications, the existence of multidisciplinary teams focused on the follow-up of patients is essential to optimize the results. However, all health care providers should have knowledge regarding the most frequent HEN-related complications and the skills to manage these problems.
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###### 

Descriptive data related to the study population.

  Variables                    Men           Women         *p*-Value
  ---------------------------- ------------- ------------- -----------
  Number of patients           168 (54.9%)   138 (45.1%)   
  Age (years)                                              
  Mean                         70.2 ± 1.0    71.9 ± 1.4    0.330
  Median                       72.0          77.0          
  IQR ^1^                      61.3--80.0    63.5--84.0    
  Standard deviation           12.9          17.1          
  Maximum/Minimum              91.0/36.0     94.0/18.0     
  Weight (kg)                                              
  Mean                         63.9 ± 0.9    56.4 ± 1.1    \<0.001
  Median                       64.0          55.0          
  IQR ^1^                      57.0--72.0    47.9--65.0    
  Standard deviation           11.5          12.5          
  Maximum/Minimum              86.0/36.0     85.0/26.5     
  Height (m)                                               
  Mean                         1.7 ± 0.1     1.6 ± 0.0     \<0.001
  Median                       1.7           1.6           
  IQR ^1^                      1.7--1.8      1.6--1.6      
  Standard deviation           0.1           0.1           
  Maximum/Minimum              2.1/1.5       1.8/1.4       
  Body mass index (kg/m^2^)                                
  Mean                         26.1 ± 0.4    27.1 ± 0.5    0.102
  Median                       25.2          27.3          
  IQR ^1^                      22.6--29.7    22.1--31.4    
  Standard deviation           4.5           6.1           
  Maximum/Minimum              35.5/16.4     42.2/15.0     
  Place of residence                                       
  Family address               148 (48.4%)   90 (29.4%)    \<0.001
  Socio-sanitary institution   20 (6.5%)     48 (15.7%)    
  Care provider                                            
  Family                       136 (44.4%)   88 (28.8%)    \<0.001
  Paid family member           2 (0.7%)      \-            
  Employee                     14 (4.6%)     40 (13.1%)    
  Voluntary                    \-            10 (3.3%)     
  Without caregiver            16 (5.2%)     \-            
  Diagnosis                                                
  Neurological                 86 (28.1%)    108 (35.3%)   
  Oncology                     66 (21.6%)    14 (4.6%)     \<0.001
  Other diagnoses              16 (5.2%)     16 (5.2%)     

^1^ IQR = Interquartile Range.
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###### 

Descriptive results related to HEN and its administration.

  Variables                          Men              Women            *p*-Value
  ---------------------------------- ---------------- ---------------- -----------
  Number of patients                 168 (54.9%)      138 (45.1%)      
  Formula type                                                         
  Standard                           56 (18.3%)       50 (16.3%)       
  Specific Other                     60 (19.6%)       42 (13.7%)       0.003
  52 (17.0%)                         46 (15.1%)                        
  Fiber content                                                        
  Yes                                156 (50.9%)      132 (43.1%)      0.301
  No                                 12 (3.9%)        6 (2.0%)         
  Route of administration                                              
  NGT ^1^                            38 (12.4%)       48 (15.7%)       
  PEG ^2^ Other ostomies             118 (38.6%)      88 (29.0%)       0.018
  12 (3.9%)                          2 (0.7%)                          
  Method of administration                                             
  Bolus                              102 (33.3%)      68 (22.2%)       0.128
  Intermittent gravity Other                          52 (17.0%)       55 18.0%)
                                     14 (4.6%)        15 (4.9%)        
  Administration time (min)                                            
  Mean                               39.2 ± 5.6       44.3 ± 6.6       0.557
  Median                             30.0             30.0             
  IQR ^3^                            20.0--40.0       15.0--41.3       
  Standard deviation                 72.3             77.0             
  Maximum/Minimum                    720.0/3.0        780.0/3.0        
  Number of intake periods per day                                     
  Mean                               4.4 ± 0.1        4.2 ± 0.1        0.062
  Median                             5.0              4.0              
  IQR ^3^                            4.0--5.0         3.0--5.0         
  Standard deviation                 1.2              1.1              
  Maximum/Minimum                    9.0/1.0          6.0/1.0          
  Volume of the shot (mL)                                              
  Mean                               301.5 ± 10.0     338.6 ± 14.4     0.035
  Median                             290.0            300.0            
  IQR ^3^                            200.0--350.0     250.0--400.0     
  Standard deviation                 129.6            168.7            
  Maximum/Minimum                    1000.0/100.0     1250.0/200.0     
  Total daily volume (mL)                                              
  Mean                               1644.9 ± 41.8    1686.0 ± 33.2    0.442
  Median                             1535.0           1700.0           
  IQR ^3^                            1275.0--2000.0   1500.0--1800.0   
  Standard deviation                 542.1            390.1            
  Maximum/Minimum                    3400.0/700.0     3500.0/700.0     
  Probe washing (pre and post)                                         
  Yes                                143 (46.7%)      120 (39.2%)      
  No                                 25 (8.2%)        18 (5.9%)        
  Position during and after intake                                     
  Less than 45°                      148 (48.4%)      132 (43.1%)      0.018
  Equal or more than 45°             20 (6.5%)        6 (2.0%)         

^1^ NGT = nasogastric tube. ^2^ PEG = endoscopic percutaneous gastrostomy. ^3^ IQR = interquartile range.
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###### 

Number of episodes (*n*) and incidence rate (IR) of HEN-related complications.

  Variables                               Men       Women     *p*-Value
  --------------------------------------- --------- --------- -----------
  Digestive complications                                     
  Vomiting                                204/1.2   124/0.9   0.571
  Regurgitation                           433/2.6   236/1.7   0.304
  Constipation                            318/1.9   154/1.1   0.024
  DiarrheaDiarrhea                        270/1.6   84/0.6    0.004
  Abdominal distension                    582/3.5   146/1.1   0.001
  Mechanical complications of the probe                       
  Obstruction                             110/0.6   14/0.1    \<0.001
  Other complications                                         
  Aspiration pneumonia                    24/0.1    20/0.1    0.967
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###### 

Complications related to the type and modality of HEN administration.

  Complication                       HEN-related Variables    Pre-Fitting   *p*-Value         Post-Fitting   *p*-Value
  ---------------------------------- ------------------------ ------------- ----------------- -------------- -----------
  Vomiting                           Formula type: Standard                                                  
  Specific                           0.6 (0.3--1.4)           0.611         0.6 (0.2--1.4)    0.230          
  Other ^a^                          1.5 (0.7--3.1)           1.489         1.4 (0.6--3.1)    0.473          
  Administration route: PEG ^b^                                                                              
  NGT ^b^                            0.6 (0.3--1.2)           0.118         0.4 (0.2--0.9)    0.026          
  Other ^c^                          1.8 (0.5--6.3)           0.392         0.8 (0.2--3.3)    0.722          
  Administration modality: Bolus                                                                             
  Intermittent gravity               0.4 (0.2--0.9)           0.021         0.4 (0.2--0.9)    0.037          
  Other ^d^                                                                                                  
  Fiber ^e^                          3.3 (1.2--9.3)           0.025         2.6 (0.8--7.9)    0.100          
  Administration time                1.0 (1.0--1.0)           0.222         1.0 (1.0--1.0)    0.089          
  Number of intake periods per day   0.8 (0.6--1.1)           0.106         0.8 (0.6--1.1)    0.151          
  Volume of the intake               1.0 (1.0--1.0)           0.948         1.0 (1.0--1.0)    0.818          
  Total daily volume                 1.0 (1.0--1.0)           0.003         1.0 (1.0--1.0)    0.026          
  Probe washing ^f^                  1.4 (0.6--3.4)           0.396         1.4 (0.6--3.4)    0.440          
  Position ^g^                       1.9 (0.7--5.1)           0.193         1.4 (0.5--4.1)    0.492          
  Regurgitation                      Formula type: Standard                                                  
  Specific                           0.5 (0.2--1.0)           0.041         0.4 (0.2--1.0)    0.037          
  Other ^a^                          1.2 (0.6--2.3)           0.635         1.0 (0.5--2.1)    0.992          
  Route of administration: PEG ^b^                                                                           
  NGT ^b^                            0.7 (0.4--1.4)           0.349         0.4 (0.2--0.9)    0.031          
  Other ^c^                          \-                       0.999         \-                0.998          
  Administration modality: Bolus                                                                             
  Intermittent gravity               0.3 (0.2--0.7)           0.002         0.3 (0.1--0.6)    0.002          
  Other ^d^                          \-                       0.998         \-                0.908          
  Fiber ^e^                          \-                       \-            \-                \-             
  Administration time                1.0 (1.0--1.0)           0.085         1.0 (1.0--1.0)    0.122          
  Number of intake periods per day   1.3 (1.0--1.6)           0.064         1.3 (1.0--1.7)    0.039          
  Volume of the intake               1.0 (1.0--1.0)           0.015         1.0 (1.0--1.0)    0.019          
  Total daily volume                 1.0 (1.0--1.0)           0.250         1.0 (1.0--1.0)    0.683          
  Probe washing ^f^                  1.4 (0.6--3.0)           0.439         1.3 (0.6--3.1)    0.493          
  Position ^g^                       2.0 (0.8--5.0)           0.114         0.8 (0.4--1.6)    0.470          
  Constipation                       Formula type: Standard                                                  
  Specific                           0.5 (0.3--0.8)           0.012         0.4 (0.2--0.8)    0.006          
  Other ^a^                          1.4 (0.8--2.6)           0.221         1.4 (0.7--2.6)    0.343          
  Route of administration: PEG ^b^                                                                           
  NGT ^b^                            0.8 (0.5--1.4)           0.832         0.6 (0.3--1.1)    0.079          
  Other ^c^                          0.3 (0.1--1.3)           0.281         0.1 (0.0--0.6)    0.013          
  Administration modality: Bolus                                                                             
  Intermittent gravity               0.4 (0.2--0.7)           0.001         0.3 (0.2--0.6)    0.000          
  Other ^d^                          0.6 (0.3--1.5)           0.305         0.7 (0.3--1.8)    0.474          
  Fiber ^e^                          0.2 (0.1--1.0)           0.057         0.2 (0.0--0.8)    0.027          
  Administration time                1.0 (1.0--1.0)           0.082         1.6 (0.6--4.2)    0.367          
  Number of intake periods per day   0.8 (0.7--1.0)           0.058         1.0 (1.0--1.0)    0.076          
  Volume of the intake               1.0 (1.0--1.0)           0.479         0.8 (0.7--1.0)    0.072          
  Total daily volume                 1.0 (1.0--1.0)           0.036         1.0 (1.0--1.0)    0.683          
  Probe washing ^f^                  0.7 (0.4--1.5)           0.417         1.0 (1.0--1.0)    0.030          
  Position ^g^                       3.6 (1.6--8.3)           0.002         1.7 (0.8--3.4)    0.165          
  Diarrhea                           Formula type: Standard                                                  
  Specific                           0.7 (0.4--1.3)           0.295         0.6 (0.3--1.2)    0.159          
  Other ^a^                          0.7 (0.4--1.4)           0.326         0.6 (0.3--1.3)    0.192          
  Route of administration: PEG ^b^                                                                           
  NGT ^b^                            0.3 (0.2--0.5)           0.000         0.4 (0.2--0.7)    0.006          
  Other ^c^                          1.9 (0.6--5.8)           0.290         0.1 (0.1--0.7)    0.017          
  Administration modality: Bolus                                                                             
  Intermittent gravity               0.5 (0.3--0.8)           0.011         0.4 (0.2--0.8)    0.007          
  Other ^d^                          0.5 (0.2--1.4)           0.193         0.5 (0.2--1.3)    0.165          
  Fiber ^e^                          1.4 (0.5--3.9)           0.520         1.2 (0.4--3.3)    0.760          
  Administration time                1.0 (1.0--1.0)           0.690         4.5 (1.9--11.0)   0.001          
  Number of intake periods per day   1.4 (1.1--1.7)           0.010         1.0 (1.0--1.0)    0.659          
  Volume of the intake               1.0 (1.0--1.0)           0.179         1.4 (1.1--1.7)    0.011          
  Total daily volume                 1.0 (1.0--1.0)           0.429         1.0 (1.0--1.0)    0.301          
  Probe washing ^f^                  1.6 (0.8--3.1)           0.199         0.9 (0.4--2.0)    0.801          
  Position ^g^                       1.8 (0.8--4.2)           0.165         1.7 (0.7--4.0)    0.244          
  Abdominal distension               Formula type: Standard                                                  
  Specific                           1.3 (0.7--2.7)           0.402         1.0 (0.6--2.6)    0.551          
  Other ^a^                          2.6 (1.3--5.2)           0.005         2.1 (1.0--4.4)    0.053          
  Route of administration: PEG ^b^                                                                           
  NGT ^b^                            0.8 (0.4--1.4)           0.432         0.5 (0.3--0.9)    0.049          
  Other ^c^                          0.2 (0.3--4.1)           0.813         0.2 (0.1--0.9)    0.043          
  Administration modality: Bolus                                                                             
  Intermittent gravity               0.3 (0.2--0.6)           0.001         0.4 (0.2--0.7)    0.006          
  Other ^d^                          0.2 (0.1--0.7)           0.014         0.1 (0.1--0.7)    0.017          
  Fiber ^e^                          0.4 (0.1--1.8)           0.235         0.2 (0.0--0.9)    0.038          
  Administration time                0.3 (1.0--1.0)           0.323         1.0 (1.0--1.0)    0.414          
  Number of intake periods per day   1.1 (1.0--1.4)           0.269         1.1 (0.9--1.4)    0.298          
  Volume of the intake               1.0 (1.0--1.0)           0.012         1.0 (1.0--1.0)    0.171          
  Total daily volume                 1.0 (1.0--1.0)           0.018         1.0 (1.0--1.0)    0.104          
  Probe washing ^f^                  1.0 (0.5--2.2)           0.949         0.4 (1.0--1.4)    0.150          
  Position ^g^                       1.6 (0.6--3.8)           0.320         1.1 (0.4--2.7)    1.057          
  Obstruction of the probe           Formula type: Standard                                                  
  Specific                           0.6 (0.2--2.3)           0.481         0.7 (0.2--2.7)    0.555          
  Other ^a^                          0.5 (0.1--1.9)           0.328         0.5 (0.1--2.3)    0.400          
  Route of administration: PEG ^b^                                                                           
  NGT ^b^                            1.9 (0.6--5.5)           0.266         7.4 (1.6--33.8)   0.010          
  Other ^c^                          0.5 (0.1--2.5)           0.360         5.9 (0.7--50.7)   0.107          
  Administration modality: Bolus                                                                             
  Intermittent gravity               4.7 (1.0--21.2)          0.043         2.3 (0.4--12.7)   0.317          
  Other ^d^                          \-                       0.998         \-                0.998          
  Fiber ^e^                          0.4 (0.1--2.0)           0.263         0.9 (0.2--5.0)    0.897          
  Administration time                1.0 (1.0--1.0)           0.700         1.0 (1.0--1.0)    0.832          
  Number of intake periods per day   1.9 (1.3--2.8)           0.002         1.7 (1.1--2.5)    0.020          
  Volume of the intake               1.0 (1.0--1.0)           0.568         1.0 (1.0--1.0)    0.024          
  Total daily volume                 1.0 (1.0--1.0)           0.000         1.0 (1.0--1.0)    0.896          
  Probe washing ^f^                  0.5 (0.1--1.5)           0.205         1.0 (1.0--1.0)    0.028          
  Position ^g^                       0.1 (0.0--0.4)           0.000         0.1 (0.0--0.5)    0.005          
  Aspiration pneumonia               Formula type: Standard                                                  
  Specific                           2.0 (0.8--4.9)           0.153         2.1 (0.8--5.4)    0.132          
  Other ^a^                          2.4 (1.0--6.0)           0.065         2.7 (1.0--7.5)    0.054          
  Route of administration: PEG ^b^                                                                           
  NGT ^b^                            0.6 (0.3--1.3)           0.188         0.5 (0.2--1.2)    0.123          
  Other ^c^                          \-                       0.999         \-                0.996          
  Administration modality: Bolus                                                                             
  Intermittent gravity               1.1 (0.5--2.3)           0.745         0.8 (0.3--1.7)    0.532          
  Other ^d^                          0.6 (0.1--2.5)           0.446         0.9 (0.2--5.1)    0.996          
  Fiber ^e^                          0.9 (0.2--4.2)           0.929         1.0 (0.2--4.8)    0.977          
  Administration time                1.0 (1.0--1.0)           0.098         1.0 (1.0--1.0)    0.204          
  Number of intake periods per day   1.0 (0.8--1.5)           0.597         1.0 (0.8--1.4)    0.849          
  Volume of the intake               1.0 (1.0--1.0)           0.718         1.0 (1.0--1.0)    0.790          
  Total daily volume                 1.0 (1.0--1.0)           0.983         1.0 (1.0--1.0)    0.934          
  Probe washing ^f^                  1.9 (0.8--4.5)           0.139         2.0 (0.8--4.8)    0.148          

^a^ Other (hypercaloric, hyperproteic, hypercaloric-hyperproteic); ^b^ PEG = percutaneous endoscopic gastrostomy; NGT = nasogastric tube; ^c^ Other ostomies (including jejunostomy); ^d^ Other forms (including continuous gravity or pump feeding); ^e^ Fiber (yes/no); ^f^ Washing (yes/no); ^g^ position (position during intake, ≥45° or \<45° and maintained at least 1 h after intake).
